Revolution Medicines, Inc. is advancing its late-stage RAS(ON) pipeline, gaining FDA priority review, and is seen as a potential acquisition target for MRK.

The entities involved

• FDA →
  • The illegal U.S. vape market is estimated to be worth $9 billion, fueled by unauthorized imports from China, while products must meet FDA authorization standards.Sun 20:36
  • VDPHL01 and Veradermics, Incorporated are seeking FDA approval for their lead therapies targeting hair loss.Sun 20:31
• MRK →

  Visual artist and director.

  Nothing else this week.

• Ras →

  Nothing else this week.

Related events

• Cuong Do leads BioVie as its CEO. BioVie Inc is listed on the NASDAQ exchange and is seeking FDA review for its drug candidate.Aug 6
• Canandaigua National Trust Co of Florida bought a new stake in AbbVie shares and granted Breakthrough Therapy Designations for one of its drugs.Oct 8
• The FDA approved GSK's Jemperli drug, while Memorial Sloan Kettering Cancer Center was involved in the AZUR-1 trial.Oct 19
• The FDA is reviewing the BLA submission from Ultragenyx Pharmaceutical, with Eric Crombez serving as chief medical officer.Jun 7
• NIH is funding research conducted by the National Cancer Institute (NCI) toward an FDA Investigational New Drug (IND) application.Oct 15